United States-based Amgen (NASDAQ: AMGN) yesterday reported its financial results for the second quarter of 2019.
The company reported total revenues of USD5.9bn in the second quarter of 2019, down 3% compared to the second quarter of 2018.
The firm posted USD1.3bn of free cash flow in the second quarter of 2019 compared with USD1.9bn in the year-ago period. GAAP earnings per share (EPS) increased 3% to USD3.57 benefited by lower weighted-average shares outstanding.
Robert A Bradway, chairman and chief executive officer, said, 'With our newer products generating strong volume gains globally and many first-in-class medicines advancing through our pipeline, we are well positioned to serve patients and deliver long-term growth for our shareholders.'
Bavarian Nordic secures new EU contract for up to 8 million smallpox and mpox vaccine doses
Perrigo to pay quarterly dividend of USD0.290 per share
Thermo Fisher Scientific to acquire Clario Holdings, expanding clinical data capabilities
Nanoform and Revio Therapeutics partner to develop long-acting hydrogel therapy for glioma
Cumberland Pharmaceuticals adds FDA-approved oral capsule for H. pylori to commercial portfolio
IP Group positions for future royalties following Pfizer's USD7.3bn acquisition of Metsera
AstraZeneca strikes landmark drug pricing deal with US Government
Fusion Antibodies secures multi-target humanisation contract with global pharmaceutical client
Genmab to acquire Merus in USD8bn deal to strengthen oncology pipeline